Stockscreener 앱 받기
81.10
0.59%
-0.52
전일 마감가:
$81.62
열려 있는:
$81.65
하루 거래량:
1.90M
Relative Volume:
0.46
시가총액:
$32.71B
수익:
$4.03B
순이익/손실:
$576.20M
주가수익비율:
56.71
EPS:
1.43
순현금흐름:
$630.70M
1주 성능:
+13.99%
1개월 성능:
+35.61%
6개월 성능:
+17.59%
1년 성능:
-36.80%
1일 변동 폭
$80.00
$81.96
1주일 범위
$69.70
$81.96
52주 변동 폭
$57.52
$132.26
덱스컴 Stock (DXCM) Company Profile
명칭
Dexcom Inc
전화
(858) 200-0200
주소
6340 SEQUENCE DRIVE, SAN DIEGO, CA
DXCM을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
DXCM
Dexcom Inc
|
81.11 | 32.71B | 4.03B | 576.20M | 630.70M | 1.43 |
|
ABT
Abbott Laboratories
|
132.27 | 224.65B | 42.34B | 13.50B | 6.66B | 7.71 |
|
BSX
Boston Scientific Corp
|
104.51 | 151.13B | 17.55B | 2.03B | 2.72B | 1.37 |
|
SYK
Stryker Corp
|
382.32 | 139.34B | 23.22B | 2.86B | 3.58B | 7.40 |
|
MDT
Medtronic Plc
|
83.37 | 108.80B | 33.20B | 4.26B | 5.47B | 3.29 |
|
EW
Edwards Lifesciences Corp
|
75.34 | 44.25B | 5.54B | 4.18B | 259.90M | 7.00 |
덱스컴 Stock (DXCM) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-04-10 | 개시 | Mizuho | Outperform |
| 2025-02-03 | 업그레이드 | Redburn Atlantic | Neutral → Buy |
| 2025-01-16 | 업그레이드 | Robert W. Baird | Neutral → Outperform |
| 2024-07-26 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2024-07-26 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2024-05-30 | 개시 | Redburn Atlantic | Neutral |
| 2024-03-12 | 개시 | RBC Capital Mkts | Outperform |
| 2023-05-30 | 재개 | Morgan Stanley | Equal-Weight |
| 2023-04-17 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2023-03-29 | 개시 | UBS | Buy |
| 2023-01-26 | 개시 | Wolfe Research | Outperform |
| 2022-10-18 | 개시 | Barclays | Equal Weight |
| 2022-10-12 | 개시 | Jefferies | Buy |
| 2022-07-15 | 개시 | Bernstein | Outperform |
| 2022-03-02 | 재개 | BofA Securities | Buy |
| 2022-02-03 | 업그레이드 | BTIG Research | Neutral → Buy |
| 2022-01-19 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2022-01-07 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2021-10-18 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2021-07-21 | 재개 | Cowen | Outperform |
| 2021-05-28 | 업그레이드 | Wells Fargo | Underweight → Equal Weight |
| 2021-05-25 | 개시 | Barclays | Overweight |
| 2021-04-15 | 개시 | Atlantic Equities | Overweight |
| 2021-01-06 | 업그레이드 | UBS | Neutral → Buy |
| 2020-10-02 | 다운그레이드 | Wells Fargo | Equal Weight → Underweight |
| 2020-05-27 | 재확인 | Piper Sandler | Overweight |
| 2020-05-14 | 개시 | Wells Fargo | Equal Weight |
| 2020-03-05 | 개시 | Citigroup | Buy |
| 2019-11-07 | 재확인 | Canaccord Genuity | Buy |
| 2019-11-07 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2019-10-23 | 개시 | Stifel | Buy |
| 2018-11-28 | 개시 | UBS | Neutral |
| 2018-10-19 | 업그레이드 | Goldman | Sell → Neutral |
| 2018-09-12 | 업그레이드 | Northland Capital | Under Perform → Market Perform |
| 2018-08-02 | 재확인 | Canaccord Genuity | Buy |
| 2018-07-02 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2018-06-08 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2018-05-11 | 개시 | BofA/Merrill | Buy |
| 2018-05-03 | 재확인 | Canaccord Genuity | Buy |
| 2018-04-04 | 개시 | Goldman | Sell |
| 2018-04-04 | 개시 | Guggenheim | Neutral |
| 2018-03-23 | 업그레이드 | Robert W. Baird | Neutral → Outperform |
| 2018-01-04 | 다운그레이드 | Northland Capital | Market Perform → Under Perform |
| 2017-09-28 | 재확인 | Wedbush | Outperform |
모두보기
덱스컴 주식(DXCM)의 최신 뉴스
Barclays Adjusts DexCom Price Target to $93 From $90, Maintains Equal Weight Rating - marketscreener.com
DexCom (DXCM) Gets Price Target Increase from Barclays | DXCM Stock News - GuruFocus
Should You Buy DXCM Stock At $80? - Forbes
Dexcom revenue grows 12% to USD 1.036 billion in Q1 2025 - Medical Buyer
Barclays Adjusts Price Target for DexCom (DXCM) to $93 Following Q1 Results | DXCM Stock News - GuruFocus
DexCom: Growth Is Reaccelerating But Don't Ignore The Risks - Seeking Alpha
DexCom (DXCM) Shares Surge on Strong Revenue and Buyback Announcement - GuruFocus
Dexcom Stock Is Today’s Big Winner After Earnings. Why the Medtech is Soaring. - Barron's
Duolingo, CoreWeave And DexCom Are Among Top 10 Large-Cap Gainers Last Week (Apr 28-May 2): Are The Others In Your Portfolio? - Benzinga
DexCom Inc. stock outperforms competitors on strong trading day - MSN
Why DexCom Inc. (DXCM) Soared Last Week - MSN
DexCom, Inc. Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky for More InformationDXCM - ACCESS Newswire
Investors who lost money on DexCom, Inc.(DXCM) should contact Levi & Korsinsky about pending Class ActionDXCM - ACCESS Newswire
Market Indexes Rise On Strong Payroll Data; DexCom Leads Gains - Finimize
Why DexCom, Inc. (DXCM) Went Up On Friday - Insider Monkey
BTIG raises DexCom stock price target to $109 from $107 By Investing.com - Investing.com South Africa
Sector Update: Health Care - marketscreener.com
DexCom Stock Rockets Higher To Lead S&P 500 Gainers Friday - Investopedia
DexCom (NasdaqGS:DXCM) Announces US$750M Buyback and Reiterates 2025 Earnings Guidance - Yahoo Finance
DexCom Stock Rises Despite Q1 Earnings Miss & Lower Margins - Zacks Investment Research
DexCom (DXCM) Stock Rating Maintained, Price Target Lowered | DXCM Stock News - GuruFocus
Leerink Adjusts Price Target on DexCom to $101 From $95 - marketscreener.com
Trupanion Posts Better-Than-Expected Results, Joins Duolingo, DexCom, Exact Sciences And Other Big Stocks Moving Higher On Friday - Benzinga
DexCom (DXCM): Analyst Maintains Rating but Lowers Price Target - GuruFocus
DexCom (DXCM): Analyst Maintains Rating but Lowers Price Target | DXCM Stock News - GuruFocus
Redburn Atlantic Adjusts DexCom Price Target to $110 From $115 - marketscreener.com
DexCom (DXCM) Target Price Reduced by Baird Amid Mixed Q1 Result - GuruFocus
DexCom, Inc. (NASDAQ:DXCM) Q1 2025 Earnings Call Transcript - Insider Monkey
DexCom (DXCM) Target Price Reduced by Baird Amid Mixed Q1 Results | DXCM Stock News - GuruFocus
DexCom (DXCM) Sees Improved Price Target Following Strong Q1 Per - GuruFocus
DexCom (DXCM) Price Target Increased by Canaccord Following Stro - GuruFocus
DexCom (DXCM) Sees Improved Price Target Following Strong Q1 Performance | DXCM Stock News - GuruFocus
DexCom (DXCM) Price Target Lowered by Piper Sandler | DXCM Stock News - GuruFocus
DexCom (DXCM) Price Target Increased by Canaccord Following Strong Q1 Results | DXCM Stock News - GuruFocus
Decoding DexCom Inc (DXCM): A Strategic SWOT Insight - GuruFocus
DexCom Inc (DXCM) Q1 2025 Earnings Call Highlights: Strong Revenue Growth Amid Supply Challenges - Yahoo Finance
DexCom Inc (DXCM) Q1 2025 Earnings: Revenue Surpasses Estimates - GuruFocus
DXCM STOCK ALERT: A Class Action is Pending Against DexCom, Inc. for Securities Fraud; Contact BFA Law before October 21 Court Deadline if You Lost Money - ACCESS Newswire
Dexcom Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Class Action Filed Against DexCom, Inc. (DXCM) Seeking Recovery for InvestorsContact Levi & Korsinsky - ACCESS Newswire
Dexcom Reports Strong Q1 2025 Results and Strategic Growth - TipRanks
Press Release Distribution & PR Platform - ACCESS Newswire
DexCom: Q1 Earnings Snapshot - MySA
Earnings call transcript: DexCom Q1 2025 revenue beats expectations By Investing.com - Investing.com Nigeria
Earnings call transcript: DexCom Q1 2025 revenue beats expectations - Investing.com
Dexcom's Growth Fueled By Demand For Innovative Glucose Monitors - Finimize
Compared to Estimates, DexCom (DXCM) Q1 Earnings: A Look at Key Metrics - Yahoo Finance
DexCom (NASDAQ:DXCM) Exceeds Q1 Expectations - Yahoo Finance
Dexcom (DXCM) Exceeds Q1 Revenue Expectations with $1.036B | DXC - GuruFocus
DexCom Inc. Announces Fall In Q1 Bottom Line - Nasdaq
덱스컴 (DXCM) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.92%
0.14%
자본화:
|
볼륨(24시간):